חיסון נגד הרפס זוסטר

שלום, האם יש מדיניות מוסדרת לגבי חיסון נ' הרפס זוסטר בארץ? מצ"ב קישור לידיעה במדסקייפ: http://www.medscape.com/viewarticle/753283 במקרה שלי, למשל, בת 65, חליתי באבעבועות רוח בילדותי, אבל כמה קרובות משפחה שלי סבלו מהרפס זוסטר (ממש סבלו) בסביבות גיל 70. תודה מראש על תשובתך.

צריך שם וסיסמה על מנת להכנס לפי הלינק שנתת. קשה לי להבין איך זה יחסן, כי הרפס זוסטר אינו הדבקה חדשה של הוירוס, אלא רה-אקטיבציה של וירוס היושב כבר אצלך, אבל אשמח להתעדכן. אולי פשוט תעתיקי ותדביקי את הידיעה.

זהו תמליל מראיון מוקלט כנראה: השארתי בחוץ את דברי הפתיחה. Anyone who has had varicella can develop zoster, even children. However, it's most common in adults. About half of all cases occur in men and women 60 years of age and older. Zoster is more common in people who are immunocompromised and in people who are taking medications that suppress their immune systems. For example: •People with cancer, especially leukemia and lymphoma, or HIV; •People with bone marrow or solid organ transplants; or •People taking steroids, chemotherapy, or transplant-related medications. Adults with zoster are at high risk for post-herpetic neuralgia (PHN); this is the most common complication. PHN causes persistent pain in the area where the rash once was. The incidence, duration, and severity of PHN increases with age. People under 40 years old rarely get PHN; it occurs most commonly in people 60 years of age and older. Zoster is preventable with vaccination. In a clinical trial involving 38,000 adults 60 years of age or older, the vaccine reduced the risk for zoster by 51% and the risk for PHN by 67%. An observational study in a large health maintenance organization showed similar results of vaccine effectiveness. Healthcare providers can protect their patients by making sure they get vaccinated. The Advisory Committee on Immunization Practices (ACIP) recommends that adults 60 years of age and older get vaccinated against zoster. Adults should receive 1 dose. Zoster vaccine can be given to patients even if they have already had zoster, in order to prevent recurrence. Serologic testing for immunity to varicella is not needed. Patients can receive other vaccines, such as influenza and pneumococcal vaccines during the same visit. It is safe for patients who were just vaccinated to be around infants, young children, pregnant women, or people with compromised immune systems. There have not been any reports of varicella cases from exposure to persons who recently received zoster vaccine. Since the zoster vaccine contains a live, attenuated virus, it should not be given to people with compromised immune systems. Also, pregnant women or people who have had an anaphylactic reaction to any vaccine component should not get the vaccine. In March 2011, the Food and Drug Administration expanded the licensure of zoster vaccine to include adults 50-59 years old. This decision was based on results of a clinical trial that followed 22,000 participants for an average of 1.3 years. In this study, the vaccine reduced the risk for zoster by about 70% in adults 50-59 years old. After considering these results and other factors, including vaccine shortages and disease burden across various age groups, ACIP decided in June 2011 to maintain the current recommendation for vaccinating adults 60 years of age and older against zoster. However, healthcare providers can still offer the vaccine to patients 50-59 years old. Understanding the recommendations for zoster vaccine will help healthcare providers address questions from their patients. Healthcare providers can prevent zoster and its complications by understanding the risks and ensuring that patients get vaccinated.